IQ-AI Ltd (LON:IQAI) said it has received the regulatory green light in America for its StoneChecker software, which is used to assess kidney stones.
BlueRock Diamonds PLC (LON:BRD) has unearthed a second stone in excess of 20 carats from its Kareevlei mine in South Africa’s Kimberley region.
Salt Lake Potash Limited (LON:SO4 ASX:SO4) has transitioned from exploration to development at its Lake Way project in Western Australia and chief executive Tony Swiericzuk said it is “difficult for me to contain my enthusiasm”.
PowerHouse Energy Group PLC (LON:PHE) is heading in the right direction after recently joining the ranks of AIM’s revenue-earning firms.
Consilium Group Limited (LON:COIN) has hailed the recovery and “rapid maturation” of the cryptocurrency and blockchain industry as the firm looked to expand its advisory services arm.
Solo Oil PLC (LON:SOLO) executive chairman Alastair Ferguson highlighted “further significant steps” taken by the company towards its strategic goals, including rationalising its asset portfolio and strengthening its management team.
ECR Minerals PLC (LON: ECR) has turned down a farm-in offer for its Windidda gold project in Western Australia.
Tavistock Investments PLC (LON:TAVI) said trading has remained in line with market expectations and that in future it will look to improve profitability by selectively purchasing client books from retiring advisors and investing in initiatives to increase the inflows of funds under management (FUM).
NQ Minerals Limited (LON:NQMI) expects operations at Hellyer to settle down after a tricky re-start to operations at the polymetallic mine in Tasmania as it transitions to operating status with growing cash flows.
Synairgen PLC (LON:SNG) said it is presenting data at an industry conference gleaned from a phase II study of its inhaled interferon beta treatment for patients with chronic obstructive pulmonary disease (COPD).
hVIVO PLC (LON:HVO) will later on Friday deliver two presentations at the European Respiratory Society Congress, both presentations highlighting the utility of the hVIVO viral challenge model as well as helping inform trial design and endpoint selection.